NorthStar gets FDA nod for more Mo-99 filling lines

By staff writers

February 19, 2020 -- NorthStar Medical Radioisotopes has garnered U.S. Food and Drug Administration (FDA) approval for additional molybdenum-99 (Mo-99) filling lines at its Columbia, MO, facility, paving the way for increased production of the isotope, which is a precursor to technetium-99m.

The FDA approved the additional filling lines via an expedited view of a prior approval supplement to the original new drug application for the company's RadioGenix system, which was approved in 2018.

NorthStar produces nonuranium-based Mo-99 at the Columbia site in collaboration with the University of Missouri Research Reactor.

Copyright © 2020

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking